Sample Answer for WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521 Included After Question
As an advanced practice nurse, you will likely experience patient encounters with complex comorbidities. For example, consider a female patient who is pregnant who also presents with hypertension, diabetes, and has a recent tuberculosis infection. How might the underlying pathophysiology of these conditions affect the pharmacotherapeutics you might recommend to help address your patient’s health needs? What education strategies might you recommend for ensuring positive patient health outcomes?
For this Discussion, you will be assigned a patient case study and will consider how to address the patient’s current drug therapy plans. You will then suggest recommendations on how to revise these drug therapy plans to ensure effective, safe, and quality patient care for positive patient health outcomes.
RESOURCES
Be sure to review the Learning Resources before completing this activity.
Click the weekly resources link to access the resources.
WEEK 9 RESOURCES
WEEK 10 RESOURCES
To Prepare:
- Review the Resources for this module and reflect on the different health needs and body systems presented.
- Your Instructor will assign you a complex case study to focus on for this Discussion.Links to an external site.
- Consider how you will practice critical decision making for prescribing appropriate drugs and treatment to address the complex patient health needs in the patient case study you selected.
BY DAY 3 OF WEEK 9
Post a brief description of your patient’s health needs from the patient case study you assigned. Be specific. Then, explain the type of treatment regimen you would recommend for treating your patient, including the choice or pharmacotherapeutics you would recommend and explain why. Be sure to justify your response. Explain a patient education strategy you might recommend for assisting your patient with the management of their health needs. Be specific and provide examples.
You will respond to your colleagues’ posts in Week 10.
Note: For this Discussion, you are required to complete your initial post before you will be able to view and respond to your colleagues’ postings. Begin by clicking on the Reply button to complete your initial post. Remember, once you click on Post Reply, you cannot delete or edit your own posts and you cannot post anonymously. Please check your post carefully before clicking on Post Reply!
BY DAY 6 OF WEEK 10
Read a selection of your colleagues’ responses from Week 9 and respond to at least two of your colleagues on two different days who were assigned a different patient case study, and provide recommendations for alternative drug treatments to address the patient’s pathophysiology. Be specific and provide examples.
A Sample Answer For the Assignment: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
Title: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
Case Study
A 46-year-old, 230lb woman with a family history of breast cancer. She is up to date on yearly mammograms. She has a history of HTN. She complains of hot flushing, night sweats, and genitourinary symptoms. She had felt well until 1 month ago and presented to her gynecologist for her annual GYN examination and to discuss her symptoms. She has a history of ASCUS about 5 years ago on her pap; other than that, Pap smears have been normal. Home medications are Norvasc 10mg QD and HCTZ 25mg QD. Her BP today is 150/90. She has regular monthly menstrual cycles. Her LMP was one month ago.
Treatment Regimen
After analyzing the symptoms, I concluded that the patient is experiencing peri-menopausal symptoms. For many people, menopause begins around age 45 though the onset of symptoms varies across different people. She is undergoing the early stages of menopause which is a stage that begins with experiencing changes in the uterus, breasts, increased fat deposit, and the urogenital tract undergoing several changes such as a shrinking cervix, and reduced muscle tone in the pelvic area. At that age, the level of estrogen production is low hence, leading to hot flashes and night sweats. Therefore, her treatment regime will focus on taking into consideration the patient has Hypertension already. Hormone therapy will be eliminated and prescribe vaginal cream that would help her manage genitourinary symptoms such as vaginal dryness and dyspareunia (Yoo et al., 2020). Mood changes and hot flashes are common symptoms of menopause hence the patient will be prescribed low-dose antidepressants such as venlafaxine and sertraline. Besides, herbal treatment has been proven to be effective in managing vasomotor symptoms hence the patient can be prescribed black cohosh which helps in reducing many menopausal symptoms (Mahady, et al., 2002).
As people continue to age, their bones become weak and this increases their chances of suffering born fractures. Therefore, the patient will be given vitamin D supplements to the increase production of estrogen which reduces with age and reduces cases of bone fractures.
During the clinical interview, I realized that the patient is taking Norvasc 10 mg and hydrochlorothiazide (HCTZ) 25 mg. I would advise her to discontinue taking Norvasc since the drug acts as a calcium blocker hence leading to hypertension and besides, its side effects increase menopause symptoms. Since she has hypertension, I would recommend that she takes lisinopril 20 mg daily. This should help alleviate the flushing that the patient has been experiencing (Li et al., 2016). Additionally, the patient has a history of ASCUS, hence I will advise her to continue with her PAP smear exams. With her blood pressure being high currently, and the fact that she is taking Norvasc, she will be encouraged to stop Norvasc but increase the HTCZ dosage to 50mg daily. The patient is expected to come regularly for assessment and examination of the drugs and symptoms.
Patient Education Strategies
Patient education has become an effective strategy to influence patients’ behavior to start living a quality life. The patient will be educated on ways to maintain weight through diet modification, become physically active, and practice relaxation as one way to reduce the severity of menopause symptoms and chances of getting breast cancer (Paterick et al., 2017). The patient will be educated about things she needs to avoid such as the use of exogenous hormones to reduce getting breast cancer going to her family history (Stuenkel et al., 2015). All this information will be passed to the patient through her patient portal which is deemed the best instructional method for her as she can access the information from the comfort of her home.
References
Li, R. X., Ma, M., Xiao, X. R., Xu, Y., Chen, X. Y., & Li, B. (2016). Perimenopausal syndrome and mood disorders in perimenopause: prevalence, severity, relationships, and risk factors. Medicine, 95(32).
Mahady, G. B., Fabricant, D., Chadwick, L. R., & Dietz, B. (2002). Black cohosh: an alternative therapy for menopause?. Nutrition in Clinical Care, 5(6), 283-289.
Paterick, T. E., Patel, N., Tajik, A. J., &Chandrasekaran, K. (2017, January). Improving health outcomes through patient education and partnerships with patients. In Baylor University Medical Center Proceedings (Vol. 30, No. 1, pp. 112-113). Taylor & Francis.
Manson, J. E., &Kaunitz, A. M. (2016). Menopause management—getting clinical care back on track. N Engl J Med, 374(9), 803-6.
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011.
Yoo, T. K., Han, K. D., Kim, D., Ahn, J., Park, W. C., &Chae, B. J. (2020). Hormone replacement therapy, breast cancer risk factors, and breast cancer risk: a nationwide population-based cohort. Cancer Epidemiology, Biomarkers & Prevention, 29(7), 1341-1347.
Click here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
Reference
Farrell D.J., Jenkins S.G. Distribution across the USA of macrolide resistance and macrolide
resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with
respiratory tract infections: PROTEKT US 2017-2018. J Antimicrob
Chemother. 2020;54(S1):i17–i22.
Li J.Z., Winston L.G., Moore D.H. Efficacy of short-course antibiotic regimens for community-
acquired pneumonia: a meta-analysis.
A Sample Answer 2 For the Assignment: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
Title: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
The discussion is laudable on the pharmacological intervention and considerations in managing vasomotor and genitourinary symptoms of menopause and management of HTN and obesity. Hormone replacement therapy would be an appropriate intervention, given the onset of menopause symptoms. However, it is essential to note that treatment in the menopausal transition should be decided according to the frequency and severity of the symptoms, even in cases of menstruation. Still, carefully screening each individual’s risk factors is essential (Academic Committee of the Korean Society of Menopause et al., 2020). In this case, the patient presents notable risk factors, including obesity, hypertension, and a family history of breast cancer. The discussion notes that the patient has a normal mammogram annually and a family history of breast cancer. A recommendation of hormone replacement therapy is the safe approach (National Institute for Health and Care Excellence [NICE], 2019).
It is essential to note that combined estrogen–progestogen therapy (EPT) would be safer than estrogen-only hormone replacement therapy. However, Martin & Barbieri (2022) believed in the recommendations of the Endocrine Society’s 2015 Clinical Practice Guideline, which advocates calculating cardiovascular and breast cancer risks before initiating menopausal HT. Therefore, it’s a transdermal type of HT instead of oral estrogen for women with moderate risk of cardiovascular disease (CVD; 5 to 10 percent 10-year risk). On the other hand, women with a uterus suggest micronized progesterone rather than synthetic progestins such as medroxyprogesterone acetate (MPA).
According to the Academic Committee of the Korean Society of Menopause et al. (2020), while estrogen therapy (ET) is effective in alleviating the symptoms of menopause, it remains unclear how ET, when initiated during the early menopause transition, affects cardiovascular diseases and breast cancer in the long term.
Additionally, while lifestyle medications such as dietary isoflavones, black cohosh, or vitamin E may be included in treatment, evidence has demonstrated they are no more effective than a placebo (Academic Committee of the Korean Society of Menopause et al., 2020). However, weight loss and obesity management would be clinically significant. According to Chopra et al. (2019), dietary intervention utilizing caloric deficit and physical moderate-intensity physical activity (150 min/week) helps alleviate perimenopause symptoms. Another consideration in discontinuing Norvasc (amlodipine) is managing cardiovascular risk. Notably, amlodipine can raise the statin concentration and increase myopathy risk (Krasulova, Holas, & Anzenbacher, 2018).
We must take note of the many contraindications to MHT use, and these include a history of breast cancer, CHD, a previous venous thromboembolic (VTE) event or stroke, active liver disease, unexplained vaginal bleeding, high-risk endometrial cancer, or transient ischemic attack (Stuenkel et al., 2015)
References
Academic Committee of the Korean Society of Menopause, Lee, SR., Cho, MK., Cho, YJ., Chun, S., Hong, SH., Hwang, KR., Jeon, GH., Joo, JK., Kim, SK., Lee, DO., Lee, DY., Lee, ES., Song, JY., Yi, KW., Yun, BH., Shin, JH., Chae, HD., & Kim, T. (2020). The 2020 Menopausal Hormone Therapy Guidelines. Journal of menopausal medicine, 26(2), 69–98. https://doi.org/10.6118/jmm.20000Links to an external site.
Chopra, S., Sharma, K. A., Ranjan, P., Malhotra, A., Vikram, N. K., & Kumari, A. (2019). Weight Management Module for Perimenopausal Women: A Practical Guide for Gynecologists. Journal of mid-life health, 10(4), 165–172. https://doi.org/10.4103/jmh.JMH_155_19Links to an external site.
Krasulova, K., Holas, O., & Anzenbacher, P. (2018). Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity. Molecules (Basel, Switzerland), 22(11), 1879. https://doi.org/10.3390/molecules22111879Links to an external site.
Martin, K. & Barbieri, R. (2022). Treatment of menopausal symptoms with hormone therapy. In J. Mulder (Ed.). UpToDate. https://www.uptodate.com/contents/treatment-of-menopausal-symptoms-with-hormone-therapy?search=hormone%20replacement%20therapy%20for%20menopausal%20women%20adult&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H2132901265Links to an external site.
National Institute for Health and Care Excellence. (2019). Menopause: diagnosis and management. NICE. https://doi.org/https://www.ncbi.nlm.nih.gov/books/NBK552590/Links Links to an external site.to an external site.
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236
WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
A Sample Answer 3 For the Assignment: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
Title: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
As correctly stated in the discussion, the patient is presented with the signs and symptoms of perimenopause. Perimenopause is a time of menstrual transition. Menstrual transition is when most women begin to get signs and symptoms of menopause. Therefore, the patient needs to be exposed to a treatment that will ease her transition into menopause. As illustrated in the discussion, subjecting the patient to hormone replacement therapy (HRT) is impossible. The perfect solution is to present the patient with a low dose of estrogen combined with progestin. Combining these hormones will help control the patient’s perimenopause symptoms (Roberts & Hickey, 2016). The patient history of hypertension justifies using estrogen and progestin to help eliminate symptoms that include fever, hot flushing, and all the genitourinary symptoms (Rosenthal & Burchum, 2021). The dangers of the treatment proposed are anchored on taking tablets. As a result, the treatment can be offered in the format of injection, eliminating the possible spike of hypertension or the possibility of suffering cancer.
The patient is currently on Norvasc treatment for hypertension. Norvasc treatment is perfect for hypertension and, therefore, cannot be altered (Misra, Srivastava, & Zaidi, 2018). An important aspect to discuss is the use of SSRI to manage the patient’s symptoms, which include hot flushing and fevers.
There is little to no evidence that classes of antidepressants, including SSRIs, contribute to eliminating or preventing symptoms like migraine, headaches, and vomiting. As a result, it would be risky to subject the patient to SSRI as a model of symptom control. A perfect recommendation would be to offer the patient serotonin. The serotonin 1b/1d agonists (triptans) inhibit the release of vasoactive peptides, promote vasoconstriction, and block pain pathways in the brainstem migraine. Even other primary headaches and secondary headaches may also improve with triptan treatment. Serotonin is known to cause vasoconstriction of the nerve endings, thereby eliminating the patient’s pain, including headaches (Schwedt & Garza, 2022). The patient can take Fluoxetine to manage her symptoms. In terms of patient education, the patient can be subjected to an analysis of the side effects of the injected estrogen. She can also be taught effective ways to manage her hypertension. The discussion above illustrates alternative treatments that can help the patient recover. The patient’s pathophysiology, pharmacological conditions, and possible drugs influence the proposed treatment.
References
Misra, JS., Srivastava, AN., & Zaidi, ZH. (2018). Cervical cytopathological changes associated with onset of menopause. Journal of mid-life health. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332728/Links to an external site.
Schwedt, TJ., & Garza, I. (2022). Acute treatment of migraine in adults. In RP. Goddeau (Ed.). UpToDate. https://www.uptodate.com/contents/acute-treatment-of-migraine-in-adults?search=serotonin%20and%20headache&topicRef=3348&source=related_linkLinks to an external site.
Roberts, H., & Hickey, M. (2016). Managing the menopause: An update. Maturitas, 86, p53-58 https://doi.org/10.1016/j.maturitas.2016.01.007 Links to an external site..
Rosenthal, LD. & Burchum, JR. (2021. Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants – E-Book. Elsevier Health Sciences. Kindle Edition.
A Sample Answer 4 For the Assignment: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
Title: WOMEN’S AND MEN’S HEALTH, INFECTIOUS DISEASE, AND HEMATOLOGIC DISORDERS NURS 6521
A 46-year-old female patient presents with a chief complaint of hot flashes, night sweats, and GU symptoms. She has a history of obesity, HTN, and ASCUS(5 years ago). She has yearly mammograms and PAP exams. The menstrual cycle is regular, LMP 1 month ago. Family history positive for breast cancer, unknown relative. Current medications include; Norvasc 10mg daily, HCTZ 25mg daily. The patient weighs 230 lbs. and her BP is 150/90. Identified health needs to include treatment of vasomotor and genitourinary symptoms of menopause and management of HTN and obesity.
Potential Contraindications/Considerations
Treatment for hormone fluctuations that occur during perimenopause, menopause, and post-menopause varies on several factors. Treatment options differ significantly based on individual risk factors, the severity of symptoms, and patient profile (age, current medications, comorbidities). The patient presents with symptoms that indicate a decrease in estrogen levels, and treatment with hormone therapy (HT) would be appropriate. It is better to start HT immediately once symptoms of hypoestrogenism appear, before or after menopause (Chun et al., 2020). Women with primary ovarian insufficiency (POI) and premature or early menopause have higher risks of bone loss, heart disease, and cognitive or affective disorders associated with estrogen deficiency. In observational studies, these risks appear to be mitigated if HT is given until the average age of menopause (The North American Menopause Society [NAMS], 2022)
Contraindications to HT have to be considered on an individual basis. The patient has a family history of breast cancer; however, she has normal mammograms. Women with a family history of breast cancer did not have a further increased risk of breast cancer while on hormone therapy (National Institute for Health and Care Excellence [NICE], 2019). The patient is obese and has HTN, increasing her risk for CVD. HT treatment should not be initiated as a treatment for CVD; however, it can be beneficial. Based on the recent results of meta-analyzing 19 randomized controlled studies, starting hormone therapy within the first ten years of menopause led to a reduction of total mortality risk by 30% and cardiovascular mortality risk by 48% (NICE, 2019). Even though there are cardiovascular benefits, additional information must be obtained to complete a cardiac risk score. An AHA/ACC or ASCVD risk score should be calculated to help guide treatment.
Recommended Treatment
The patient reports that the onset of vasomotor and GU symptoms are relatively new. She does not indicate that the symptoms are intense or severe at this time. Treatment should start by recommending lifestyle modifications, including weight loss. In women who need relief for mild vasomotor symptoms, NAMS (2019), recommends first considering lifestyle changes, either alone or combined with a nonprescription remedy, such as dietary isoflavones, black cohosh, or vitamin E. Weight loss, regular exercise, a healthy diet, and avoiding alcohol can all help decrease the symptoms of menopause. If these methods do not provide relief of the vasomotor symptoms, then Brisdelle 7.5mg daily will be prescribed. Brisdelle (SSRI), was approved in 2013 for the treatment of vasomotor symptoms in menopause (Rosenthal & Rosenjack Burchum, 2021). The GU/vaginal symptoms will be treated with vaginal estrogen therapy (ET), specifically Premarin. Vaginal estrogen reduces urinary urgency, urinary frequency, overactive bladder, and urinary incontinence by reducing the contraction of bladder muscles via increasing the blood flow around the bladder neck and urethra (Chun et al., 2020). Low-dose vaginal estrogen is effective and safe, and all types of topical estrogen medicine (cream, vaginal tablet, and vaginal ring) are effective in reducing the symptoms and signs of vaginal atrophy (NAMS, 2022) It is currently recommended that treatment with low-dose vaginal ET be limited to less than one year.
The patient’s blood pressure is elevated, and her Norvasc will be discontinued for two reasons. First, Norvasc is a CYP3A4 inhibitor, and estrogen is a major substrate of CYP3A4. Additionally, clonidine has been successful in treating hot flashes and could provide more effective antihypertensive effects as well.
Recommended Education
One strategy to improve patient outcomes is to provide engaging, patient-centered education. Menopause can be overwhelming, with symptoms that can be sensitive for women to discuss. Patient education needs to be ongoing and should start before menopause or menopause symptoms occur. Education should include expected signs and symptoms and treatment options. Education should encompass risks, benefits, and side effects of HT, nonpharmacologic, and lifestyle modifications. Patients need to be aware of the increased risk of osteoporosis, cardiovascular disease, depression, other mental health conditions, and changes in vaginal health that need ongoing monitoring. Screenings, including pelvic exams, mammograms, pap smears, and bone density/bone density scans, will be essential to the health care plan (National Menopause Foundation, 2022). Additional education should include lifestyle modifications, including consuming foods that contain calcium or taking calcium supplements, vitamin D supplements, regular aerobic and strength-building exercise, limiting alcohol, and smoking cessation (National Menopause Foundation, 2022)
Conclusion
Menopause treatment requires a comprehensive health exam that identifies the benefits and risks of all treatment options. HT is the most effective treatment for menopause symptoms. However, several risk factors and contraindications need to be considered before initiating. Ongoing monitoring of symptoms and response to treatment provide improved patient outcomes. Patient education should focus on lifestyle modifications, symptom management, testing and screening to reduce risk factors, and a pharmacologic regimen that is highly individualized.
References
Chun, S., Hong, S.-H., Lee, S. R., Kyoung, M., Hwang, K. R., Kim, S. K., Lee, E. S., Song, J. Y., & Kim, T. (2020). The 2020 menopausal hormone therapy guidelines. Journal of Menopausal Medicine, 26(2), 69–98. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475284/Links to an external site.
National Institute for Health and Care Excellence. (2019). Menopause: diagnosis and management. NICE. https://doi.org/https://www.ncbi.nlm.nih.gov/books/NBK552590/Links to an external site.
National Menopause Foundation. (2022, August 16). Education. https://nationalmenopausefoundation.org/education/Links to an external site.
Rosenthal, L. D., & Rosenjack Burchum, J. (2021). Lehne’s pharmacotherapeutics for advance practice nurses and physician assistants (2nd ed.). Elsevier.
The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. The Journal of The North American Menopause Society, 29(7), 767–794. https://www.menopause.orgLinks to an external site.
Grading Rubric
| Performance Category | 100% or highest level of performance
100% 16 points |
Very good or high level of performance
88% 14 points |
Acceptable level of performance
81% 13 points |
Inadequate demonstration of expectations
68% 11 points |
Deficient level of performance
56% 9 points
|
Failing level
of performance 55% or less 0 points |
| Total Points Possible= 50 | 16 Points | 14 Points | 13 Points | 11 Points | 9 Points | 0 Points |
| Scholarliness
Demonstrates achievement of scholarly inquiry for professional and academic topics. |
Presentation of information was exceptional and included all of the following elements:
|
Presentation of information was good, but was superficial in places and included all of the following elements:
|
Presentation of information was minimally demonstrated in all of the following elements:
|
Presentation of information is unsatisfactory in one of the following elements:
|
Presentation of information is unsatisfactory in two of the following elements:
|
Presentation of information is unsatisfactory in three or more of the following elements
|
| 16 Points | 14 Points | 13 Points | 11 Points | 9 Points | 0 Points | |
| Application of Course Knowledge
Demonstrate the ability to analyze and apply principles, knowledge and information learned in the outside readings and relate them to real-life professional situations |
Presentation of information was exceptional and included all of the following elements:
|
Presentation of information was good, but was superficial in places and included all of the following elements:
|
Presentation of information was minimally demonstrated in the all of the following elements:
|
Presentation of information is unsatisfactory in one of the following elements:
|
Presentation of information is unsatisfactory in two of the following elements:
|
Presentation of information is unsatisfactory in three of the following elements
|
| 10 Points | 9 Points | 6 Points | 0 Points | |||
| Interactive Dialogue
Initial post should be a minimum of 300 words (references do not count toward word count) The peer and instructor responses must be a minimum of 150 words each (references do not count toward word count) Responses are substantive and relate to the topic. |
Demonstrated all of the following:
|
Demonstrated 3 of the following:
|
Demonstrated 2 of the following:
|
Demonstrated 1 or less of the following:
|
||
| 8 Points | 7 Points | 6 Points | 5 Points | 4 Points | 0 Points | |
| Grammar, Syntax, APA
Points deducted for improper grammar, syntax and APA style of writing. The source of information is the APA Manual 6th Edition Error is defined to be a unique APA error. Same type of error is only counted as one error. |
The following was present:
AND
AND
|
The following was present:
AND/OR
AND/OR
|
The following was present:
AND/OR
AND/OR
|
The following was present:
AND/OR
AND/OR
|
The following was present:
AND/OR
AND/OR
AND/OR
|
The following was present:
AND/OR
AND/OR
|
| 0 Points Deducted | 5 Points Lost | |||||
| Participation
Requirements |
Demonstrated the following:
|
Failed to demonstrate the following:
|
||||
| 0 Points Lost | 5 Points Lost | |||||
| Due Date Requirements | Demonstrated all of the following:
A minimum of one peer and one instructor responses are to be posted within the course no later than Sunday, 11:59 pm MT. |
Demonstrates one or less of the following.
A minimum of one peer and one instructor responses are to be posted within the course no later than Sunday, 11:59 pm MT. |